As α-tubulin deacetylation through HDAC6 activity has already been established as a possible therapy in cancer clinical trials35, we suggest that its targeting may be a viable therapeutic option for cardiomyopathy caused by mutations in LMNA. Here, HDAC6 is linked to cardiomyopathy.